STOCKHOLM, Aug 31 (Reuters) - Bayer’s (BAYGn.DE) anticoagulant Xarelto showed a similar safety profile compared with standard therapy in clinical trial results released on Tuesday, keeping it in the multibillion-dollar race to replace the old and troublesome drug warfarin.
